Salarius Pharmaceuticals, Inc. (SLRX)
| Market Cap | 38.17M |
| Revenue (ttm) | 4.70M |
| Net Income (ttm) | -8.81M |
| Shares Out | 44.76M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,320,782 |
| Open | 0.880 |
| Previous Close | 0.890 |
| Day's Range | 0.803 - 0.890 |
| 52-Week Range | 0.632 - 3.500 |
| Beta | 1.85 |
| Analysts | Strong Buy |
| Price Target | 4.63 (+443.2%) |
| Est. Earnings Date | Nov 4, 2021 |
About SLRX
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. The company's lead candidate is Seclidemstat (SP-2577), which is in Phase I/II clinical trial for the treatment of advanced solid tumors, including prostate, breast, and ovarian cancers, as well as Ewing sarcoma. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, ...
Financial Performance
In 2020, SLRX's revenue was $5.23 million, an increase of 51.03% compared to the previous year's $3.47 million. Losses were -$7.35 million, 6.00% more than in 2019.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for SLRX stock is "Strong Buy." The 12-month stock price forecast is 4.63, which is an increase of 443.17% from the latest price.
News
Salarius Pharmaceuticals and Nationwide Children's Hospital Disclose Research Findings from Presentation at 2021 AACR...
HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...
Salarius Pharmaceuticals to Present at the 2021 BioFuture Conference
HOUSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...
Salarius Pharmaceuticals and Nationwide Children's Hospital Announce Poster Presentation at the 2021 AACR-NCI-EORTC V...
HOUSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cance...
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...
Salarius Pharmaceuticals and Fox Chase Cancer Center Launch Research Partnership
HOUSTON, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...
Salarius Pharmaceuticals Added to FTSE Global Micro Cap Index
HOUSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...
Salarius Pharmaceuticals to Present at the Virtual Life Science Investor Forum
HOUSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...
Salarius Pharmaceuticals to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference
HOUSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pedia...
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediat...
4 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
Salarius Pharmaceuticals Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
Clinical Trial in Hematologic Cancers Initiated and Initial Patients Enrolled in Expanded Sarcoma Clinical Trial; Multiple Potential Data Readouts Expected in 2021 and 2022
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET Conference Call and Live Audio Webcast Scheduled for Thursday, August 5, 2021, 10:00 a.m. ET
Salarius Pharmaceuticals Announces Aundrietta Duncan, Ph.D., To Present During Virtual Epigenetic Therapeutic Targets...
Dr. Duncan will discuss seclidemstat's potential in treating FET-rearranged sarcomas Dr. Duncan will discuss seclidemstat's potential in treating FET-rearranged sarcomas
Salarius Pharmaceuticals Adds Fox Chase Cancer Center to Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarco...
Clinical Trial Now Expands to Nine U.S. Trial Sites Clinical Trial Now Expands to Nine U.S. Trial Sites
Salarius Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference
HOUSTON, July 09, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancer...
REMINDER: Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
Online Event Scheduled for Monday, June 21, 2021, at 2:00 p.m., ET
Salarius Pharmaceuticals Launches Mid-Stage Blood Cancer Trial With Seclidemstat
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) has initiated an investigator-initiated Phase 1/2 trial to investigate seclidemstat as a potential treatment for hematologic cancers. The trial will be an ope...
Salarius Pharmaceuticals Announces New Clinical Trial to Study Seclidemstat in Hematologic Cancers
Clinical trial to target patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML), both cancers that can progress into Acute Myeloid Leukemia (AML) Clinical trial to targ...
Salarius Pharmaceuticals to Host Virtual Key Opinion Leader and Investor Event
Online Event Scheduled for Monday, June 21, 2021 at 2:00 p.m., ET
Salarius' Seclidemstat Shows Single-Agent Drug Activity in Heavily Pre-Treated Sarcomas Patients
Salarius Pharmaceuticals Inc (NASDAQ: SLRX) presented data at the American Society of Clinical Oncology Virtual Annual Meeting for seclidemstat, a reversible inhibitor of the lysine-specific histone dem...
Salarius Pharmaceuticals Presents New Research Data Demonstrating Seclidemstat's Safety, Dosing, and Drug Activity at...
Presentations highlight full data from dose-escalation stage of Phase 1/2 clinical trial in Ewing sarcoma and interim data from Advanced Solid Tumor (AST) trial
Salarius Pharmaceuticals Discloses Key Findings from Three Abstracts to be Presented at American Society of Clinical ...
Preliminary drug activity observed in both relapsed/refractory Ewing sarcoma and Advanced Solid Tumor (AST) trials
Penny Stocks On Robinhood For You May 2021 Watch List
Robinhood penny stocks to watch for the next half of May The post Penny Stocks On Robinhood For You May 2021 Watch List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Salarius Pharmaceuticals: Q1 Earnings Insights
Shares of Salarius Pharmaceuticals (NASDAQ:SLRX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 72.73% year over year to ($0.06), which mis...
Salarius Pharmaceuticals Reports First Quarter Financial Results with Business Highlights
Cash and Cash Equivalents of $36.6M, More Than Sufficient to Fund Completion of the Current Clinical Trials of Lead Drug Candidate, Seclidemstat